Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biodexa Pharmaceuticals ( (BDRX) ) has shared an update.
On March 18, 2026, Biodexa Pharmaceuticals announced a change to the ratio of its American Depositary Receipts, shifting from one ADR representing 100,000 ordinary shares to one ADR representing 500,000 ordinary shares, effective on or about April 6, 2026. ADR holders will be required to exchange five existing ADRs for one new ADR in what is effectively a one-for-five reverse ADR split, with fractional entitlements sold and proceeds distributed, while the company’s underlying ordinary shares remain unaffected.
The move is intended to lift the company’s ADR price to meet Nasdaq’s $1.00 minimum bid price requirement, signaling management’s effort to maintain the U.S. listing and address compliance concerns. JP Morgan Chase Bank, as depositary, will coordinate the mandatory exchange process with holders, making the action operationally significant for investors in Biodexa’s U.S.-traded securities.
The most recent analyst rating on (BDRX) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
The score is pressured primarily by weak financial performance (zero 2024 revenue, persistent losses, and significant ongoing cash burn) and bearish technicals (price well below key moving averages with negative MACD). Valuation does not provide a clear offset due to negative earnings and no dividend yield data.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker BDRX. It focuses on developing a pipeline of innovative therapies targeting rare diseases with significant unmet medical needs, positioning the firm within the niche orphan-disease drug development segment of the healthcare sector.
Average Trading Volume: 334,216
Technical Sentiment Signal: Sell
Current Market Cap: $488K
See more insights into BDRX stock on TipRanks’ Stock Analysis page.